Table 1.
General and specific clinical signs, morbidities, and mortalities of differentially PPMV-1 virus-vaccinated groups 14 days post-challenge, with clarification of the healthy condition in the vaccinated, non-challenged groups.
| Groups | Subgroups | General Signs * |
Respiratory Signs |
Greenish Diarrhoea |
Nervous Signs | Morbidity (%) | Clinical Indices ** |
Mortality (%) |
|---|---|---|---|---|---|---|---|---|
| G1 | A | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 (0) | 0 | 0/8 (0) |
| B | 5/8 | 0/8 | 2/8 | 2/8 | 5/8 (62.5) | 0.66 | 3/8 (37.5) | |
| G2 | A | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 (0) | 0 | 0/8 (0) |
| B | 1/8 | 0/8 | 1/8 | 0/8 | 1/8 (12.5) | 0.01 | 0/8 (0) | |
| G3 | A | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 (0) | 0 | 0/8 (0) |
| B | 1/8 | 0/8 | 0/8 | 1/8 | 1/8 (12.5) | 0.02 | 0/8 (0) | |
| G4 | A | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 (0) | 0 | 0/8 (0) |
| B | 8/8 | 1/8 | 5/8 | 6/8 | 8/8 (100) | 1.03 | 5/8 (62.5) |
(*) General signs: ruffled feathers, lethargy, and anorexia. (**) Clinical indices: calculated as previously mentioned in the materials. Subgroups G1a, G2a, and G3a were vaccinated with live NDV LaSota, inactivated PPMV, and simultaneous NDV LaSota and PPMV vaccines, respectively, without challenge. Subgroups G1b, G2b, and G3b were vaccinated with live NDV LaSota, inactivated PPMV, and simultaneous NDV LaSota and PPMV vaccines, respectively, and challenged with PPMV-1 strain. However, G4a and G4b were kept non-vaccinated and non-challenged and challenged, respectively.